308.78
前日終値:
$307.99
開ける:
$306.45
24時間の取引高:
532.05K
Relative Volume:
0.52
時価総額:
$39.64B
収益:
$2.35B
当期純損益:
$-269.70M
株価収益率:
-147.74
EPS:
-2.09
ネットキャッシュフロー:
$-75.39M
1週間 パフォーマンス:
+1.57%
1か月 パフォーマンス:
+8.23%
6か月 パフォーマンス:
+26.55%
1年 パフォーマンス:
+92.52%
Alnylam Pharmaceuticals Inc Stock (ALNY) Company Profile
名前
Alnylam Pharmaceuticals Inc
セクター
電話
(617) 551-8200
住所
675 WEST KENDALL STREET, CAMBRIDGE, MA
ALNY を他の銘柄と比較する
株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
---|---|---|---|---|---|---|
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
308.78 | 39.64B | 2.35B | -269.70M | -75.39M | -2.09 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
450.91 | 114.57B | 11.10B | -988.90M | -1.26B | -3.92 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
522.68 | 55.88B | 14.09B | 4.50B | 2.96B | 39.28 |
![]()
ARGX
Argen X Se Adr
|
551.22 | 35.64B | 2.58B | 1.06B | -1.28B | 16.33 |
![]()
ONC
Beone Medicines Ltd Adr
|
264.42 | 28.55B | 3.81B | -644.79M | -669.77M | -6.24 |
Alnylam Pharmaceuticals Inc Stock (ALNY) Upgrades & Downgrades
日付 | アクション | アナリスト | 評価の変更 |
---|---|---|---|
2025-03-31 | 開始されました | Redburn Atlantic | Buy |
2025-03-24 | アップグレード | JP Morgan | Neutral → Overweight |
2024-11-12 | ダウングレード | Wolfe Research | Peer Perform → Underperform |
2024-10-16 | 開始されました | Scotiabank | Sector Outperform |
2024-08-16 | アップグレード | Goldman | Neutral → Buy |
2024-02-16 | ダウングレード | Goldman | Buy → Neutral |
2024-02-15 | 開始されました | Wolfe Research | Peer Perform |
2023-12-08 | 開始されました | Wells Fargo | Equal Weight |
2023-10-11 | ダウングレード | Oppenheimer | Outperform → Perform |
2023-09-29 | 開始されました | Raymond James | Outperform |
2023-05-05 | アップグレード | BMO Capital Markets | Market Perform → Outperform |
2023-04-26 | 開始されました | SMBC Nikko | Neutral |
2023-03-21 | 開始されました | Bernstein | Outperform |
2023-01-18 | 開始されました | Canaccord Genuity | Buy |
2022-09-09 | 再開されました | Morgan Stanley | Equal-Weight |
2022-07-13 | 開始されました | Cantor Fitzgerald | Neutral |
2022-06-27 | ダウングレード | Guggenheim | Buy → Neutral |
2022-06-07 | 開始されました | William Blair | Outperform |
2022-04-25 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
2022-03-01 | 開始されました | Citigroup | Buy |
2022-02-03 | アップグレード | Guggenheim | Neutral → Buy |
2022-01-03 | アップグレード | Piper Sandler | Neutral → Overweight |
2021-11-22 | アップグレード | Goldman | Neutral → Buy |
2021-11-22 | アップグレード | RBC Capital Mkts | Sector Perform → Outperform |
2021-11-01 | アップグレード | Oppenheimer | Perform → Outperform |
2021-10-04 | アップグレード | UBS | Neutral → Buy |
2021-08-04 | ダウングレード | Piper Sandler | Overweight → Neutral |
2021-02-22 | ダウングレード | Guggenheim | Buy → Neutral |
2021-02-12 | ダウングレード | Citigroup | Buy → Neutral |
2021-02-12 | 繰り返されました | H.C. Wainwright | Buy |
2021-01-25 | ダウングレード | BMO Capital Markets | Outperform → Market Perform |
2020-09-30 | 再開されました | Berenberg | Hold |
2020-09-08 | 開始されました | Citigroup | Buy |
2020-08-11 | ダウングレード | Oppenheimer | Outperform → Perform |
2020-05-13 | 開始されました | RBC Capital Mkts | Sector Perform |
2020-05-07 | ダウングレード | JP Morgan | Overweight → Neutral |
2020-04-24 | 再開されました | Evercore ISI | Outperform |
2020-03-19 | 開始されました | Berenberg | Buy |
2019-12-19 | 繰り返されました | Chardan Capital Markets | Buy |
2019-11-20 | 開始されました | Oppenheimer | Outperform |
2019-11-13 | 開始されました | BofA/Merrill | Buy |
2019-05-23 | 再開されました | Goldman | Neutral |
2019-04-12 | 開始されました | Evercore ISI | Outperform |
2019-03-06 | アップグレード | Evercore ISI | In-line → Outperform |
2019-03-05 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
2019-01-23 | 開始されました | UBS | Neutral |
2018-10-01 | 開始されました | Cantor Fitzgerald | Overweight |
2018-08-13 | 繰り返されました | Stifel | Buy |
2018-08-07 | アップグレード | Stifel | Hold → Buy |
2018-05-04 | 繰り返されました | Stifel | Hold |
2018-03-28 | 開始されました | Evercore ISI | In-line |
すべてを表示
Alnylam Pharmaceuticals Inc (ALNY) 最新ニュース
Here's How Much You Would Have Made Owning Alnylam Pharmaceuticals Stock In The Last 20 Years - Benzinga
Antisense Oligonucleotides Market is expected to reach US$ - openPR.com
Exploring High Growth Tech Stocks In The US This June 2025 - simplywall.st
Alnylam Pharmaceuticals’ SWOT analysis: stock poised for growth in expanding ATTR-CM market - Investing.com Canada
Acute Intermittent Porphyria Market Predicted to See Upsurge - openPR.com
From Kentucky farm to founding Biogen: New documentary traces life of Phil Sharp - The Business Journals
Where are the Opportunities in (ALNY) - news.stocktradersdaily.com
Primary Hyperoxaluria Pipeline 2025: FDA Updates, Therapy - openPR.com
Healey boosts life sciences tax incentives as 33 companies plan major expansions - The Business Journals
ALNY Stock: JP Morgan Raises Price Target to $338 | ALNY Stock N - GuruFocus
What 18 Analyst Ratings Have To Say About Alnylam Pharmaceuticals - Benzinga
Homozygous Familial Hypercholesterolemia Market to Reach New - openPR.com
Homozygous Familial Hypercholesterolemia Market to Reach New Heights in Growth by 2034, DelveInsight Predicts | Arrowhead Pharma, Novartis, Alnylam Pharma, LIB Therapeutics, Amryt Pharma - The Globe and Mail
JPMorgan Ups Price Target for Alnylam (ALNY) Following Amvuttra Forecast Revision | ALNY Stock News - GuruFocus
Alnylam Wins EC Nod for Label Expansion of Amvuttra for ATTR-CM - MSN
The European Commission Approves Alnylam’s AMVUTTRA - Insider Monkey
John Maraganore joins Axion Bio board to advance cancer therapy By Investing.com - Investing.com Canada
Former Alnylam CEO Who Built $40B Company Backs Instil Bio's Novel Cancer Drug Program - Stock Titan
EC approves Alnylam’s vutrisiran for ATTR-CM treatment - Yahoo Finance
Latest Federal Court Cases: Alnylam Pharmaceuticals, Inc. v. Moderna, Inc. - JD Supra
Dyslipidemia Market to Reach New Heights in Growth by 2034, - openPR.com
Alnylam gets EU approval for Amvuttra in heart disorder treatment - MSN
Alnylam Receives European Commission Approval for AMVUTTRA® (vut - GuruFocus
European Approval Expansion for Alnylam's (ALNY) AMVUTTRA | ALNY Stock News - GuruFocus
Alnylam (ALNY) Secures EU Approval for Amvuttra in Cardiomyopathy - GuruFocus
Transcript : Alnylam Pharmaceuticals, Inc. Presents at Goldman Sachs 46th Annual Global Healthcare Conference 2025, Jun-09-2025 09 - marketscreener.com
Alnylam Gets EU Approval for RNAi Drug to Treat Transthyretin Amyloidosis With Cardiomyopathy - marketscreener.com
EC approves first RNAi therapy for ATTR cardiomyopathy By Investing.com - Investing.com Nigeria
Alnylam Receives European Commission Approval for AMVUTTRA® (vutrisiran) for the Treatment of ATTR Amyloidosis with Cardiomyopathy | ALNY Stock News - GuruFocus
(vutrisiran) for the Treatment of ATTR Amyloidosis with Cardiomyopathy - Business Wire
siRNA on the Precipice as Candidates Reach Beyond the Liver - BioSpace
AMVUTTRA® (vutrisiran) Significantly Reduces Mortality and a Range of Important Cardiovascular Events in Patients with ATTR Amyloidosis with Cardiomyopathy: Additional Data from HELIOS-B - mx.advfn.com
SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Alnylam Pharmaceuticals, Inc. (ALNY) - ACCESS Newswire
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation Involving Possible Securities Fraud Violations by Officers of Alnylam Pharmaceuticals, Inc. (ALNY) - ACCESS Newswire
Alnylam, Incyte and GSK led biopharma gains amid earnings volatility - BioWorld MedTech
Fed Circ upholds Moderna’s COVID-19 vaccine win against Alnylam - Life Sciences Intellectual Property Review
Moderna Beats Alnylam Appeal In COVID Vaccine Patent Case - Benzinga
Alnylam Fails to Revive Patent Infringement Suit Against Moderna - Bloomberg Law News
Strict Standard for Overriding Patent Lexicography in COVID Vaccine Patent Battle - Patently-O
CAFC Affirms Moderna’s Win, Holding Alnylam Narrowly Defined ‘Branched Alkyl’ - IPWatchdog.com
US appeals court sides with Moderna on COVID patent claims - Reuters
Huntington’s Disease Clinical Trial Pipeline Analysis: 20+ Key Companies Shaping the Future of Dopamine Receptor Antagonists Therapeutics | DelveInsight - GlobeNewswire Inc.
Alnylam Pharmaceuticals (ALNY) Price Target Raised to $500 by H.C. Wainwright - Insider Monkey
(ALNY) Pivots Trading Plans and Risk Controls - news.stocktradersdaily.com
Alnylam stock soars to all-time high of $304.52 By Investing.com - Investing.com South Africa
Alnylam stock soars to all-time high of $304.52 - Investing.com Australia
JPMorgan lifts Alnylam stock price target to $330 By Investing.com - Investing.com Canada
Why Alnylam Could Outperform In The Transthyretin Amyloidosis With Cardiomyopathy Field - Seeking Alpha
Alnylam to Webcast Presentation at Goldman Sachs 46th Annual Global Healthcare Conference - BioSpace
RNAi Leader Alnylam Set for Major Presentation at Goldman Sachs Healthcare Conference - Stock Titan
Alnylam Co-Founder Who Developed First FDA-Approved RNAi Drug Joins TransCode's Cancer Mission - Stock Titan
Alnylam Pharmaceuticals Inc (ALNY) 財務データ
収益
当期純利益
現金流量
EPS
大文字化:
|
ボリューム (24 時間):